SHENZHEN, China, Sept. 17 /PRNewswire-FirstCall/ -- HTDS http://www.htdsmedical.com/ The Company is pleased to provide the following update to its shareholders and followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based subsidiary; and other general business matters. On Monday, September 14, 2009, the company announced its H1N1 project status: http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds.
In order to keep our followers updated and advised HTDS management is mindful that it will have to provide a series of updates as it makes progress on the HTDS' H1N1 initiatives. This is the company mandate while maintaining the integrity of various confidential and non-disclosure agreements it may have in force.
To that end, HTDS' Mellow Hope China based subsidiary has established a very close partnership with one of the biggest Pharmaceutical manufacturers in China. In this partnership, Mellow Hope acts as an exclusive agent and partner for its H1N1 Vaccine sales and marketing in the International markets. Up to today, the clinical trial of Influenza A (H1N1) Vaccine (Split Virion) through this Pharmaceutical manufacturer has been completed and approved. The H1N1 Vaccine manufacturing license will be granted soon. Again, due to confidentiality, competition, non disclosure, and other factors HTDS will not disclose the name of the Vaccine manufacturer in China until it obtains its manufacturing. HTDS future press releases and filings will address this.
The following statements were made by officials, which we hope may shed some more light on this. Like other countries, China has made its plan for vaccine stocks to prevent possible new outbreaks of A(H1N1) flu later this year. Vaccination usually is first carried out among high risk groups and vulnerable people such as medics, the elderly and children, not necessarily the entire population.
"China will be able to produce enough influenza A(H1N1) vaccines for 65 million people by the end of this year," health minister Chen Zhu said Friday.
(65 million is only about 5% of China's 1.3 billion, population)
In other company news the company is compiling a video of its offices and infrastructure in China which it will post shortly on its web site http://www.htdsmedical.com/. The company has also completed its filings on Pink Sheets with supporting legal opinion to have the Caveat Emptor rank removed, and has heard back from Pink Sheets. A minor revision is required to the V1 before the Caveat Emptor ranking is removed. This is currently being addressed and V2 will be uploaded shortly. Both V1 and V2 versions will remain displayed for our followers review. The company continues to address the short position it believes exists on its security, and regrets any inconvenience the recent Pink Sheets actions caused.
Market Data 
Markets 
AI
